Newron Pharmaceuticals SpA

"The real game changer is the next drug coming, that’s Evenamide: an innovative treatment for patients suffering from schizophrenia. If we look ahead to the next 6 months, the most exciting thing will be that we get a first partner on board and then the start of the one-year, double-blind, placebo-controlled landmark study in patients with treatment-resistant schizophrenia.” explains Stefan Weber, CEO of Newron Pharmaceuticals SpA Pharmaceuticals at #EKF24 hosted by @DeutscheBoerseCashMarket.   Newron is focused on research and development of innovative CNS compounds. With its lead compound, the Company intends to change the treatment paradigm in #schizophrenia. 🧠   🎥Watch the full interview here: https://lnkd.in/dJg7gjYQ   #Newron #Evenamide #Neuroscience #NovelTherapies #DeutschesEigenkapitalforum

Newron Pharmaceuticals SpA is pleased to announce that our CEO, Stefan Weber, will be attending the #DeutschesEigenkapitalforum 2024 from November 25 to 26. As one of Europe´s premier forums for equity and debt capital financing, the #EKF brings together industry leaders, investors, and innovators. Stefan will present on Monday, November 25, at 15:15 CET, discussing progress made with our lead program #Evenamide, our investigational add-on therapy for chronic and treatment-resistant #schizophrenia. We look forward to connecting and showcasing our strategic plans to advancing innovative treatments addressing unmet needs in CNS disorders. #EKF24 #Biotech #InvestorRelations #Networking #Newron

Stefan Weber, CEO of #Newron, will be at the @Jefferies London Healthcare Conference 2024, the largest healthcare-dedicated conference in Europe, taking place on November 19 – 21, 2024. We look forward to engaging with an audience of hundreds of public and private healthcare companies, institutional and private equity investors, and VCs, showcasing Newron’s commitment to advancing innovative therapies for patients with diseases of the central and peripheral nervous system (CNS). Stefan will be discussing progress made with #Evenamide, our investigational add-on treatment for chronic and treatment-resistant #schizophrenia, as we continue our clinical journey and partnership discussions. #JefferiesHealthcare #CNSDisorders #InnovationInHealth #Biotech #Partnering

We are excited to be part of the 37th ECNP Congress, 21-24 September 2024   𝐉𝐨𝐢𝐧 𝐞𝐯𝐞𝐧𝐚𝐦𝐢𝐝𝐞 𝐬𝐞𝐬𝐬𝐢𝐨𝐧 𝐨𝐧 ‘𝐒𝟏𝟒 – 𝐍𝐞𝐰 𝐌𝐞𝐝𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐒𝐲𝐦𝐩𝐨𝐬𝐢𝐮𝐦’ 𝐌𝐨𝐧𝐝𝐚𝐲, 𝟐𝟑𝐫𝐝 𝐒𝐞𝐩𝐭𝐞𝐦𝐛𝐞𝐫 𝟏𝟓.𝟎𝟎-𝟏𝟔.𝟑𝟎 https://lnkd.in/ecfX9Wfz   See you in Milan or virtually! #ECNP2024 #neuroscience #psychiatry #Newron #NovelTherapies #evenamide #schizophrenia  

Today we announced the H1 2024 results and provided an update on our business activities. Read the full news here https://lnkd.in/d54FDnFP #Newron #NovelTherapies #results #evenamide #schizophrenia

At Newron Pharmaceuticals SpA, we were honored to host three distinguished schizophrenia experts presenting at our 2024 Investor Day - each sharing their perspective on the unmet needs and the potential of our lead candidate, Evenamide, as future treatment option. 🔍 Expert Contributions: - Prof. Anthony Grace, Ph.D.offered insights into the role of hippocampal activity in schizophrenia symptoms - Prof John Kane, M.D.discussed the challenges and shortcomings of current treatments for treatment-resistant schizophrenia (TRS) - Prof. Stephen Marder, M.D.emphasized the unprecedented results of evenamide in long-term studies  🚀 The knowledge from these specialists supports the hard work preparing our upcoming clinical trial to secure Evenamide’s road to registration, as a first add-on therapy for TRS. You can catch up on all the presentations by watching the full webcast here 👉https://lnkd.in/dQ-iUZEM #Evenamide #InvestorDay2024 #Newron #PharmaNews #Schizophrenia #Biotech #Innovators #Treatment

🎉 𝐒𝐮𝐜𝐜𝐞𝐬𝐬𝐟𝐮𝐥 𝐈𝐧𝐯𝐞𝐬𝐭𝐨𝐫 𝐃𝐚𝐲 𝟐𝟎𝟐𝟒! 🎉 We are thrilled to share the full webcast from our Investor Day held in New York City with you all! Our CEO, Stefan Weber, and CMO, Ravi Anand, alongside top schizophrenia experts, unveiled promising insights and developments regarding Evenamide, our lead compound currently in a phase III program for treatment-resistant schizophrenia (TRS). 🔬 𝐊𝐞𝐲 𝐓𝐚𝐤𝐞𝐚𝐰𝐚𝐲𝐬: 𝐁𝐫𝐞𝐚𝐤𝐭𝐡𝐫𝐨𝐮𝐠𝐡 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐑𝐞𝐬𝐮𝐥𝐭𝐬: Latest trials show Evenamide's unique mechanism could revolutionize care for TRS patients 𝐄𝐱𝐩𝐞𝐫𝐭 𝐄𝐧𝐝𝐨𝐫𝐬𝐞𝐦𝐞𝐧𝐭𝐬: Leading schizophrenia specialists predict that earlier use of Evenamide would benefit patients with inadequate responses 𝐋𝐨𝐧𝐠-𝐓𝐞𝐫𝐦 𝐈𝐦𝐩𝐚𝐜𝐭: Newly presented data suggests Evenamide may also change the long-term course of schizophrenia Want to know more? Click here to watch the full webcast now! 👉 https://lnkd.in/dQ-iUZEM #Evenamide #InvestorDay2024 #Newron #PharmaNews #Schizophrenia #biotech #innovators #treatment

📢 Don’t miss out on the chance to register for our 2024 Investor Day, taking place on June 25 in New York!   This is a fantastic opportunity to listen to three of the world's leading #KeyOpinionLeaders in neuroscience and schizophrenia, who will be reviewing and presenting the very latest finding's from Newron Pharmaceuticals SpA's evenamide program, and how it affects patients suffering from treatment-resistant schizophrenia. Our CEO Stefan Weber and CMO Ravi Anand there in person, who will be hosting the event and revealing the exciting updates from evenamide's ongoing clinical and registration program.   Join live on site or via webcast. Register now by clicking below! ⬇️⬇⬇ https://lnkd.in/ebFHJWk5   #evenamide #InvestorDay2024 #Newron #PharmaNews #Schizophrenia #Results #biotech #innovators #treatment

<< #MeettheSpeakers for our 2024 Investor Day on June 25 in New York City:   Stephen Marder MD, is one of three internationally recognized #KeyOpinionLeaders. He is Daniel X. Freedman Professor of Psychiatry at the Semel Institute of Neuroscience & Human Behavior and Director of the Section of Psychosis at UCLA’s Neuropsychiatric Institute. He will discuss the implications of clinical data from studies evaluating evenamide, a glutamate modulator, as an add-on medication for the treatment of schizophrenia and TRS. 📚🧠 Don’t miss it! Register now to join our Investor Day live or online: https://lnkd.in/ebFHJWk5 📅✨

#MeettheSpeakers for our 2024 Investor Day on June 25 in New York City:   Anthony Grace, PhD, is one of the three internationally recognized #KeyOpinionLeaders. He is Editor-in-Chief at the international Journal of Neuropsychopharmacology, Distinguished Professor of Neuroscience and Professor of Psychiatry and Psychology at the University of Pittsburgh,   Don’t miss his presentation of breakthrough pre-clinical data on the neurobiology of treatment-resistant schizophrenia! 📚🧠   Register now to join our Investor Day live or online: https://lnkd.in/ebFHJWk5 📅✨   #Newron #NovelTherapies #results #evenamide #schizophrenia